PHARMACOLOG I UPPSALA AB Financials Pharmacolog i Uppsala AB
Equities
PERP B
SE0019071812
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.099 SEK | +9.76% |
|
+11.24% | +74.91% |
| 24/04 | Perpetua Medical AB Appoints Camilla Lonn as CFO | CI |
| 23/04 | Pharmacolog i Uppsala AB will Change its Ticker to PERP B from PHLOG B | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 20.55 | 76.41 | 69.09 | 139.8 | 47.47 | 3.75 |
| Enterprise Value (EV) 1 | 8.737 | 61.2 | 54.96 | 121.4 | 37.16 | -1.728 |
| P/E ratio | -1.29 x | -3.95 x | -3.82 x | -9.02 x | -2.09 x | -0.13 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 19.9 x | 35 x | 49.9 x | 15.9 x | 4.69 x | 0.38 x |
| EV / Revenue | 8.45 x | 28.1 x | 39.7 x | 13.8 x | 3.67 x | -0.17 x |
| EV / EBITDA | -0.74 x | -4.14 x | -5.03 x | -9.13 x | -1.99 x | 0.09 x |
| EV / FCF | -1.26 x | -7.35 x | -8.8 x | -10.9 x | -2.77 x | 0.16 x |
| FCF Yield | -79.7% | -13.6% | -11.4% | -9.14% | -36.1% | 614% |
| Price to Book | 1.5 x | 4.49 x | 4.75 x | 6.71 x | 3.38 x | 0.46 x |
| Nbr of stocks (in thousands) | 7,088 | 9,924 | 12,724 | 15,375 | 19,475 | 66,250 |
| Reference price 2 | 2.900 | 7.700 | 5.430 | 9.090 | 2.438 | 0.0566 |
| Announcement Date | 08/04/19 | 29/04/20 | 05/05/21 | 02/05/22 | 23/05/23 | 16/04/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.035 | 2.182 | 1.385 | 8.816 | 10.11 | 9.936 |
| EBITDA 1 | -11.78 | -14.79 | -10.92 | -13.3 | -18.72 | -18.31 |
| EBIT 1 | -12.3 | -15.32 | -11.18 | -13.68 | -19.11 | -18.49 |
| Operating Margin | -1,189.03% | -702.16% | -807.19% | -155.22% | -188.94% | -186.11% |
| Earnings before Tax (EBT) 1 | -12.39 | -16.73 | -16 | -13.71 | -19.16 | -18.28 |
| Net income 1 | -12.39 | -16.73 | -16 | -13.71 | -19.16 | -18.28 |
| Net margin | -1,197.17% | -766.8% | -1,155.15% | -155.54% | -189.48% | -183.94% |
| EPS 2 | -2.249 | -1.949 | -1.422 | -1.008 | -1.168 | -0.4399 |
| Free Cash Flow 1 | -6.961 | -8.326 | -6.243 | -11.1 | -13.4 | -10.61 |
| FCF margin | -672.85% | -381.64% | -450.67% | -125.91% | -132.49% | -106.77% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 08/04/19 | 29/04/20 | 05/05/21 | 02/05/22 | 23/05/23 | 16/04/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 11.8 | 15.2 | 14.1 | 18.3 | 10.3 | 5.48 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -6.96 | -8.33 | -6.24 | -11.1 | -13.4 | -10.6 |
| ROE (net income / shareholders' equity) | -99.2% | -109% | -101% | -76.6% | -110% | -165% |
| ROA (Net income/ Total Assets) | -46.3% | -50.2% | -36.4% | -38.4% | -53.7% | -74.2% |
| Assets 1 | 26.76 | 33.3 | 43.97 | 35.72 | 35.66 | 24.64 |
| Book Value Per Share 2 | 1.940 | 1.720 | 1.140 | 1.350 | 0.7200 | 0.1200 |
| Cash Flow per Share 2 | 1.910 | 1.670 | 1.190 | 1.240 | 0.5500 | 0.0800 |
| Capex 1 | 0.41 | 0.23 | 0.2 | 0.18 | - | - |
| Capex / Sales | 39.21% | 10.54% | 14.75% | 2.06% | - | - |
| Announcement Date | 08/04/19 | 29/04/20 | 05/05/21 | 02/05/22 | 23/05/23 | 16/04/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +74.91% | 9L | |
| -12.09% | 1.92TCr | |
| -39.00% | 295.88Cr | |
| +22.02% | 196.26Cr | |
| -0.62% | 169.05Cr | |
| +33.51% | 126.82Cr | |
| -16.17% | 98Cr | |
| -22.01% | 91Cr | |
| +5.38% | 80Cr | |
| -23.80% | 63Cr |
- Stock Market
- Equities
- PERP B Stock
- Financials Pharmacolog i Uppsala AB
